Platform & Pipeline
Patients
Inside Kyverna
Education & Events
Investors
News
Careers
Contact

Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease

by Creative Pace | May 10, 2024

Search

Recent Comments

Links

Home
Platform & Pipeline
Patients
Inside Kyverna
Education & Events
Investors
Careers
Contact

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

Privacy Policy (US)
Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress